Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type

被引:80
|
作者
Higashi, Michiyo [1 ]
Yamada, Norishige [1 ]
Yokoyama, Seiya [1 ]
Kitamoto, Sho [1 ]
Tabata, Kazuhiro [1 ]
Koriyama, Chihaya [2 ]
Batra, Surinder K. [3 ,4 ]
Yonezawa, Suguru [1 ]
机构
[1] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, Kagoshima 8908544, Japan
[2] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Epidemiol & Prevent Med, Kagoshima 8908544, Japan
[3] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Biochem, Omaha, NE USA
[4] Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Dept Mol Biol, Omaha, NE USA
关键词
Cholangiocarcinoma; MUC16; CA125; Prognosis; PROGNOSTIC-FACTOR; EXTRACELLULAR SUPERSTRUCTURE; SURGICAL-TREATMENT; CA-125; GENE; MUC4; MUCINS; CA125; NEOPLASMS; CARCINOMA; DIAGNOSIS;
D O I
10.1159/000335164
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Objectives: MUC16 carries the peptide epitope CA125, which is well known as a marker of ovarian cancer. High serum levels of MUC16 (CA125) have been reported not only in patients with ovarian cancer but also in patients with liver diseases. We evaluated the expression of MUC16 in intrahepatic cholangiocarcinoma-mass forming type (ICC-ME) tissues. Methods: We examined the expression of MUC16 by immunohistochemical analyses using the monoclonal antibody M11 in ICC-MF tissues from 63 patients. To compare the prevalence of each mucin expression by clinicopathological features, appropriate statistical analysis was performed. Results: MUC16 was detected in 48% of samples (30/63). After adjusting for the effects of other prognostic factors, multi-variate survival analysis revealed that MUC16 expression is a significant independent factor of poor prognosis (p = 0.005). Conclusion:The current results indicate that MUC16 expression is a prognostic factor of poor survival in ICC-MF. Copyright (C) 2012 S. Karger AG, Basel
引用
收藏
页码:101 / 106
页数:6
相关论文
共 50 条
  • [41] Developing a mass spectrometry–based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap)
    Naviya Schuster-Little
    Sergio Madera
    Rebecca Whelan
    Analytical and Bioanalytical Chemistry, 2020, 412 : 6361 - 6370
  • [42] CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells
    Reinartz, Silke
    Failer, Sophie
    Schuell, Tina
    Wagner, Uwe
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (10) : 1558 - 1569
  • [43] Pre-clinical comparison of approaches to increasing the immunogenicity of CA125 (MUC16) DNA vaccines
    Ragupathi, Govind
    Koide, Fusataka
    Yin, Beatrice Wt
    Lloyd, Kenneth O.
    Hannaman, Drew
    Livingston, Philip O.
    CANCER RESEARCH, 2006, 66 (08)
  • [44] Regulation of MUC16 (CA125) release in ovarian cancer cells by cytokines and growth factors.
    Spriggs, E
    Spriggs, C
    Thapi, D
    Awtry, C
    Spriggs, DR
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9139S - 9140S
  • [45] Integrated genomic analysis identifies PLEC1 as a molecular target of MUC16/CA125
    Blum, A.
    Tanner, E.
    Bisogna, M.
    Dao, F.
    Thapi, D.
    Spriggs, D.
    Levine, D.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S162 - S162
  • [46] PPAR Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells
    Morgado, Micaela
    Carson, Daniel D.
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2017, 118 (01) : 163 - 171
  • [47] Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
    Takahiro Einama
    Yoji Yamagishi
    Yasuhiro Takihata
    Takafumi Suzuki
    Tamio Yamasaki
    Yuichi Hirose
    Kazuki Kobayashi
    Naoto Yonamine
    Ibuki Fujinuma
    Takazumi Tsunenari
    Makiko Koga
    Yusuke Ishibashi
    Ken Nagata
    Takehiro Shiraishi
    Akiko Nakazawa
    Toshimitsu Iwasaki
    Eiji Shinto
    Kimi Kato
    Kimiya Sato
    Hideki Ueno
    Yoji Kishi
    Hitoshi Tsuda
    Biomarker Research, 9
  • [48] Determination and analysis of HLA-A2 epitopes on ovarian cancer antigen CA125 (MUC16)
    Schultes, Birgit C.
    Hou, Fuxiang
    Nicodemus, Christopher F.
    JOURNAL OF IMMUNOLOGY, 2006, 176 : S268 - S269
  • [49] Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
    Einama, Takahiro
    Yamagishi, Yoji
    Takihata, Yasuhiro
    Suzuki, Takafumi
    Yamasaki, Tamio
    Hirose, Yuichi
    Kobayashi, Kazuki
    Yonamine, Naoto
    Fujinuma, Ibuki
    Tsunenari, Takazumi
    Koga, Makiko
    Ishibashi, Yusuke
    Nagata, Ken
    Shiraishi, Takehiro
    Nakazawa, Akiko
    Iwasaki, Toshimitsu
    Shinto, Eiji
    Kato, Kimi
    Sato, Kimiya
    Ueno, Hideki
    Kishi, Yoji
    Tsuda, Hitoshi
    BIOMARKER RESEARCH, 2021, 9 (01)
  • [50] Developing a mass spectrometry-based assay for the ovarian cancer biomarker CA125 (MUC16) using suspension trapping (STrap)
    Schuster-Little, Naviya
    Madera, Sergio
    Whelan, Rebecca
    ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2020, 412 (24) : 6361 - 6370